Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external ...

Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...

Researchers from Creatv Bio, Division of Creatv MicroTech, Inc. (Monmouth Junction, NJ) and The Mayo Clinic (Jacksonville, FL), in collaboration with BriaCell Therapeutics Corporation (Philadelphia, ...

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external light-dark cycles.

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

In addition, SV-BR-1_GM therapy appeared to upregulate PD-L1 expression in ... from the blood of the cancer patient. CAMLs are macrophages that have engulfed tumor cells from tumor site.